8EQ Stock Overview
A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cytek Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.20 |
| 52 Week High | US$6.90 |
| 52 Week Low | US$4.20 |
| Beta | 1.32 |
| 11 Month Change | 42.20% |
| 3 Month Change | 24.00% |
| 1 Year Change | n/a |
| 33 Year Change | -62.65% |
| 5 Year Change | n/a |
| Change since IPO | -69.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8EQ | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 11.7% | 3.9% | 0.8% |
| 1Y | n/a | 5.4% | 9.1% |
Return vs Industry: Insufficient data to determine how 8EQ performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how 8EQ performed against the German Market.
Price Volatility
| 8EQ volatility | |
|---|---|
| 8EQ Average Weekly Movement | 12.4% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8EQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8EQ's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 645 | Wenbin Jiang | cytekbio.com |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.
Cytek Biosciences, Inc. Fundamentals Summary
| 8EQ fundamental statistics | |
|---|---|
| Market cap | €803.89m |
| Earnings (TTM) | -€9.68m |
| Revenue (TTM) | €191.71m |
4.3x
P/S Ratio-84.8x
P/E RatioIs 8EQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8EQ income statement (TTM) | |
|---|---|
| Revenue | US$201.21m |
| Cost of Revenue | US$90.71m |
| Gross Profit | US$110.50m |
| Other Expenses | US$120.66m |
| Earnings | -US$10.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 54.92% |
| Net Profit Margin | -5.05% |
| Debt/Equity Ratio | 0.8% |
How did 8EQ perform over the long term?
See historical performance and comparison